2. Search Result
Search Result
Results for "

hepatic metabolism

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

1

Fluorescent Dye

3

Biochemical Assay Reagents

8

Peptides

11

Natural
Products

8

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1134
    Imazalil
    1 Publications Verification

    Enilconazole

    		 Pregnane X Receptor (PXR) Fungal Infection
    Imazalil (Enilconazole) is a fungicide. Imazalil has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil is commonly used to protect various agricultural crops against fungal attack. Imazalil induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .
    Imazalil
  • HY-B1134A
    Imazalil sulfate
    1 Publications Verification

    Enilconazolel sulfate

    		 Fungal Pregnane X Receptor (PXR) Infection
    Imazalil (Enilconazole) sulfate is a fungicide. Imazalil sulfate has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil sulfate is commonly used to protect various agricultural crops against fungal attack. Imazalil sulfate induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .
    Imazalil sulfate
  • HY-13771A
    Ursodeoxycholic acid sodium
    15+ Cited Publications

    Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium

    		 G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite Metabolic Disease Inflammation/Immunology Cancer
    Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
    Ursodeoxycholic acid sodium
  • HY-13771
    Ursodeoxycholic acid
    15+ Cited Publications

    Ursodeoxycholate; Ursodiol; UDCA

    		 G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Infection Metabolic Disease Cancer
    Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
    Ursodeoxycholic acid
  • HY-13771R
    Ursodeoxycholic acid (Standard)

    Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)

    		 Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Infection Metabolic Disease Cancer
    Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
    Ursodeoxycholic acid (Standard)
  • HY-120374
    V-PYRRO/NO

    		Biochemical Assay Reagents Metabolic Disease
    V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.
    V-PYRRO/NO
  • HY-B0171S
    Antipyrine-d3

    Phenazone-d3; Phenazon-d3

    		 Isotope-Labeled Compounds Inflammation/Immunology
    Antipyrine-d3 is the deuterium labeled Antipyrine. Antipyrine (Phenazone) is an antipyretic and analgesic. Antipyrine can be used as a probe agent for oxidative agent metabolism. Antipyrine has been widely used in assessment of hepatic oxidative capacity .
    Antipyrine-d3
  • HY-B1134R
    Imazalil (Standard)

    Enilconazole (Standard)

    		 Reference Standards Fungal Infection
    Imazalil (Standard) is the analytical standard of Imazalil. This product is intended for research and analytical applications. Imazalil (Enilconazole) is a fungicide. Imazalil has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil is commonly used to protect various agricultural crops against fungal attack. Imazalil induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .
    Imazalil (Standard)
  • HY-110260
    LDN-193188

    		Endogenous Metabolite Metabolic Disease
    LDN-193188 is a Phosphatidylcholine transfer protein (PC-TP) inhibitor. LDN-193188 regulates hepatic glucose metabolism, and can be used for study of glucose metabolism .
    LDN-193188
  • HY-113104
    Androsterone glucuronide

    ADT-G

    		 Endogenous Metabolite Drug Metabolite Metabolic Disease
    Androsterone glucuronide (ADT-G) is one of the main metabolites of oral testosterone in humans and can be found in urine. The level of Androsterone glucuronide can reflect the absorption and hepatic metabolism of testosterone .
    Androsterone glucuronide
  • HY-B0171R
    Antipyrine (Standard)

    Phenazone (Standard); Phenazon (Standard)

    		 Fluorescent Dye Reference Standards Inflammation/Immunology
    Antipyrine (Standard) is the analytical standard of Antipyrine. This product is intended for research and analytical applications. Antipyrine (Phenazone) is an antipyretic and analgesic. Antipyrine can be used as a probe agent for oxidative agent metabolism. Antipyrine has been widely used in assessment of hepatic oxidative capacity .
    Antipyrine (Standard)
  • HY-P11358
    IRW

    		Angiotensin-converting Enzyme (ACE) Acetyl-CoA Carboxylase Mitochondrial Metabolism Inflammation/Immunology
    IRW is an orally active tripeptide produced from egg white with angiotensin converting enzyme (ACE) inhibitory properties. IRW can prevent high-fat diet (HFD)-induced Non-alcoholic fatty liver disease (NAFLD) by modulating hepatic lipid metabolism and increasing mitochondrial content. IRW decreases hepatic triglyceride content and lipid droplet size. IRW increases the hepatic mitochondrial complexes and citrate synthase activity, phosphorylation of 5’-AMP-activated protein kinase and microsomal triglyceride transfer protein abundance. IRW increases phosphorylated acetyl CoA carboxylase and mitochondrial complexes, IRW can be used for the research of inflammation .
    IRW
  • HY-168049
    ZLY06

    		PPAR Akt Metabolic Disease
    ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .
    ZLY06
  • HY-123442
    L 775,606

    		5-HT Receptor Neurological Disease
    L 775,606 is a potent and selective 5-HT1D receptor agonist. L 775,606 can be used to study migraine headache .
    L 775,606
  • HY-B1334
    Perhexiline
    5 Publications Verification

    		 Mitochondrial Metabolism Apoptosis Cardiovascular Disease Cancer
    Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina .
    Perhexiline
  • HY-B1334A
    Perhexiline maleate
    5 Publications Verification

    		 Mitochondrial Metabolism Apoptosis Cardiovascular Disease Cancer
    Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
    Perhexiline maleate
  • HY-124950
    Picumeterol

    GR114297A

    		 Adrenergic Receptor Others
    Picumeterol (GR114297A) is a potent and selective β2-adrenoceptor agonist with bronchodilator and anti-bronchoconstrictor effects. Picumeterol produces long-lasting relaxation of airways smooth muscle both in vitro and in vivo. Picumeterol is cleared from plasma through a rapid and extensive hepatic metabolism. Picumeterol is proming for rasearch of asthma and related diseases .
    Picumeterol
  • HY-N0157C
    Orotic acid potassium
    3 Publications Verification

    6-Carboxyuracil potassium; Vitamin B13 potassium

    		 Endogenous Metabolite DNA/RNA Synthesis Metabolic Disease
    Orotic acid potassium (Vitamin B13 potassium) is a precursor of pyrimidine bases and is involved in the synthesis of DNA and RNA. Orotic acid potassium stimulates the growth of animals, plants and microorganisms, participates in carbohydrate metabolism, and is necessary for the growth and life activities of organisms. Orotic acid potassium is a measurement indicator in routine newborn screening for urea cycle abnormalities. Orotic acid potassium can cause hepatic steatosis and hepatomegaly in rats .
    Orotic acid potassium
  • HY-E70413
    Amino acid arylamidase, hog kidney

    		Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Amino acid arylamidase, hog kidney is a metalloprotease that can hydrolyze proteins or peptides containing free α-amino or α-imino groups, playing a crucial role in amino acid metabolism and protein digestion. Its hydrolytic activity can be blocked by acetylation of the N-terminus. Amino acid arylamidase, hog kidney can be used in research on hepatic diseases, biliary diseases, and heart failure .
    Amino acid arylamidase, hog kidney
  • HY-B0859
    MCPA
    1 Publications Verification

    		 Herbicide Cytochrome P450 Metabolic Disease
    MCPA is an orally active phenoxyacetic acid herbicide. MCPA interferes with membrane integrity, energy metabolism (decreases ATP levels), and redox balance in plant cells. MCPA increases hepatic cytochrome P-450 levels and increases aniline hydroxylase and 7-ethoxycoumarin O-deethylase activities. MCPA can be used to control broadleaf weeds .
    MCPA
  • HY-P10337
    OXM-7

    		GCGR GLP Receptor Metabolic Disease Endocrinology
    OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
    OXM-7
  • HY-174133
    HSD17B13-IN-104

    		17β-HSD Metabolic Disease Inflammation/Immunology
    HSD17B13-IN-104 (Compound 32) is an orally active, highly potent and selective HSD17B13 inhibitor (IC50=2.5 nM). HSD17B13-IN-104 regulates hepatic lipid metabolism by inhibiting the SREBP-1c/FAS pathway. HSD17B13-IN-104 blocks HSD17B13 enzymatic activity to improve hepatic lipid accumulation. HSD17B13-IN-104 is promising for research of metabolic dysfunction-associated steatohepatitis .
    HSD17B13-IN-104
  • HY-129982
    SC-435

    		Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
    SC-435
  • HY-B1334AR
    Perhexiline maleate (Standard)

    		Mitochondrial Metabolism Apoptosis Cardiovascular Disease Cancer
    Perhexiline (maleate) (Standard) is the analytical standard of Perhexiline (maleate). This product is intended for research and analytical applications. Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
    Perhexiline maleate (Standard)
  • HY-120696
    SR9186

    ML368

    		 Cytochrome P450 Parasite Infection Cancer
    SR9186 (ML368) is a selective CYP3A4 inhibitor with IC50 values of 9, 4, and 38 nM for Midazolam → 1'-hydroxymidazolam, Testosterone → 6β-hydroxytestosterone, and Vincristine → Vincristine M1, respectively. SR-9186 inhibits the development of hepatic-stage P. falciparum and blocks ivermectin metabolism. SR-9186 can be used in breast cancer research .
    SR9186
  • HY-33914
    4-Hydroxymethylpyrazole

    		Drug Metabolite Metabolic Disease
    4-Hydroxymethylpyrazole is the primary metabolite of Fomepizole (HY-B0876) produced through hepatic oxidative metabolism. 4-Hydroxymethylpyrazole exhibits a plasma concentration that is positively correlated with the administered dosage of Fomepizole, and it demonstrates a relatively short half-life. 4-Hydroxymethylpyrazole demonstrates inhibitory effects on alcohol dehydrogenase (ADH) in both humans and monkeys, but its inhibition constant is significantly higher than that of Fomepizole, rendering its in vivo impact negligible .
    4-Hydroxymethylpyrazole
  • HY-B0859S1
    MCPA-d3

    		Isotope-Labeled Compounds Herbicide Cytochrome P450 Metabolic Disease
    MCPA-d3 is the deuterium labeled MCPA (HY-B0859). MCPA is an orally active phenoxyacetic acid herbicide. MCPA interferes with membrane integrity, energy metabolism (decreases ATP levels), and redox balance in plant cells. MCPA increases hepatic cytochrome P-450 levels and increases aniline hydroxylase and 7-ethoxycoumarin O-deethylase activities. MCPA can be used to control broadleaf weeds .
    MCPA-d3
  • HY-W001542R
    5-Hydroxyoxindole (Standard)

    		Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Cancer
    5-Hydroxyoxindole is a structural analog of uric acid for its antioxidant. 5-Hydroxyoxindole has DPPH radical scavenging activities and lipid peroxidation-inhibitory activities. 5-Hydroxyoxindole is a product of partial metabolism of tryptophan involving conversion in the gut lumen of tryptophan to indole through the action of bacterial tryptophanase and tryptophan synthase. 5-Hydroxyoxindole is one of the main molecules responsible for the neurological symptoms of hepatic encephalopathy in rats. 5-Hydroxyoxindole can be used for the research of oxidative stress-mediated disorders .
    5-Hydroxyoxindole (Standard)
  • HY-B1907A
    Rifamycin

    Rifamycin SV

    		 Antibiotic Bacterial DNA/RNA Synthesis Infection Inflammation/Immunology
    Rifamycin (Rifamycin SV) is an orally active ansamycin antibiotic. Rifamycin inhibits DNA-dependent RNA synthesis. Rifamycin has antibacterial activity against Mycobacterium tuberculosis. Rifamycin interferes with hepatic bile acid metabolism. Rifamycin has anti-inflammatory effects. Rifamycin can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .
    Rifamycin
  • HY-B0859S
    MCPA-13C8

    4-Chloro-2-Methylphenoxyacetic acid-13C8

    		 Isotope-Labeled Compounds Herbicide Cytochrome P450 Metabolic Disease
    MCPA- 13C8 is the 13C-labeled MCPA (HY-B0859). MCPA is an orally active phenoxyacetic acid herbicide. MCPA interferes with membrane integrity, energy metabolism (decreases ATP levels), and redox balance in plant cells. MCPA increases hepatic cytochrome P-450 levels and increases aniline hydroxylase and 7-ethoxycoumarin O-deethylase activities. MCPA can be used to control broadleaf weeds .
    MCPA-13C8
  • HY-B1907
    Rifamycin sodium

    Rifamycin SV sodium

    		 Antibiotic Bacterial DNA/RNA Synthesis Infection Inflammation/Immunology
    Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .
    Rifamycin sodium
  • HY-B0859R
    MCPA (Standard)

    		Herbicide Reference Standards Cytochrome P450 Metabolic Disease
    MCPA (Standard) is the analytical standard of MCPA (HY-B0859). This product is intended for research and analytical applications. MCPA is an orally active phenoxyacetic acid herbicide. MCPA interferes with membrane integrity, energy metabolism (decreases ATP levels), and redox balance in plant cells. MCPA increases hepatic cytochrome P-450 levels and increases aniline hydroxylase and 7-ethoxycoumarin O-deethylase activities. MCPA can be used to control broadleaf weeds .
    MCPA (Standard)
  • HY-W001542
    5-Hydroxyoxindole

    		Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Cancer
    5-Hydroxyoxindole is a structural analog of uric acid for its antioxidant. 5-Hydroxyoxindole has DPPH radical scavenging activities and lipid peroxidation-inhibitory activities. 5-Hydroxyoxindole is a product of partial metabolism of tryptophan involving conversion in the gut lumen of tryptophan to indole through the action of bacterial tryptophanase and tryptophan synthase. 5-Hydroxyoxindole is one of the main molecules responsible for the neurological symptoms of hepatic encephalopathy in rats. 5-Hydroxyoxindole can be used for the research of oxidative stress-mediated disorders .
    5-Hydroxyoxindole
  • HY-33914R
    4-Hydroxymethylpyrazole (Standard)

    		Drug Metabolite Reference Standards Metabolic Disease
    4-Hydroxymethylpyrazole (Standard) is an analytical standard for 4-Hydroxymethylpyrazole (HY-33914). This product is intended for research and analytical applications. 4-Hydroxymethylpyrazole is the primary metabolite of fomepizole (HY-B0876) via hepatic oxidative metabolism. 4-Hydroxymethylpyrazole exhibits a plasma concentration that is positively correlated with the administered dosage of Fomepizole, and it demonstrates a relatively short half-life. 4-Hydroxymethylpyrazole inhibits alcohol dehydrogenase (ADH) in humans and monkeys, but the inhibition constant is much higher than that of fomepizole and is therefore negligible in vivo
    4-Hydroxymethylpyrazole (Standard)
  • HY-13771S1
    Ursodeoxycholic acid-13C

    Ursodeoxycholate-13C; Ursodiol-13C; UDCA-13C

    		 Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite Cancer
    Ursodeoxycholic acid- 13C is the 13C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
    Ursodeoxycholic acid-13C
  • HY-118816
    11β-Prostaglandin F2α

    11-epi PGF2α-EA; 11β-PGF2α-EA; 11β-Prostamide F2α

    		 Drug Metabolite Metabolic Disease
    11β-Prostaglandin F2α ethanolamide (11β-PGF2α-EA) is the theoretical hepatic metabolite of PGD2-EA, produced during COX-2 metabolism of the endogenous cannabinoid AEA which is found in brain, liver, and other mammalian tissues.1 AEA can be used directly by COX-2 and specific PG synthase to produce ethanolamide congeners of the classical PGs. PGD2-EA is formed in activated RAW 264.7 cells treated with AEA.
    11β-Prostaglandin F2α
  • HY-B1907R
    Rifamycin sodium (Standard)

    Rifamycin SV sodium (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Rifamycin (sodium) (Standard) is the analytical standard of Rifamycin (sodium). This product is intended for research and analytical applications. Rifamycin sodium (Rifamycin SV sodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .
    Rifamycin sodium (Standard)
  • HY-Y0319G
    Magnesium acetate tetrahydrate
    4 Publications Verification

    		 Endogenous Metabolite AMPK Reactive Oxygen Species (ROS) Caspase Fungal PPAR Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Magnesium acetate tetrahydrate is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Magnesium acetate tetrahydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Magnesium acetate tetrahydrate regulates energy metabolism. Magnesium acetate tetrahydrate has anticancer activity against gastric cancer. Magnesium acetate tetrahydrate induces writhing reaction and ulcerative colitis. Magnesium acetate tetrahydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain .
    Magnesium acetate tetrahydrate
  • HY-113478S
    Ursodeoxycholic acid-d4

    Ursodeoxycholate-d4; Ursodiol-d4; UDCA-d4

    		 Isotope-Labeled Compounds Infection Metabolic Disease
    Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .
    Ursodeoxycholic acid-d4
  • HY-141645
    IMM-H007

    WS070117

    		 AMPK TGF-β Receptor NF-κB JNK AP-1 Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis .
    IMM-H007
  • HY-123765
    JTT-553

    		Acyltransferase Metabolic Disease
    JTT-553 is a DGAT1 inhibitor (IC50: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM) .
    JTT-553
  • HY-114118
    Semaglutide
    Maximum Cited Publications
    23 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide
  • HY-114118B
    Semaglutide acetate
    Maximum Cited Publications
    23 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide acetate
  • HY-114118F
    Semaglutide, FITC labeled

    		GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide, FITC labeled is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide, FITC labeled
  • HY-114118S1
    Semaglutide-d8 tetraTFA

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8 tetraTFA
  • HY-114118A
    Semaglutide TFA
    Maximum Cited Publications
    23 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide TFA
  • HY-114118S
    Semaglutide-d8

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8
  • HY-114118S3
    Semaglutide-13C6,15N TFA

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Metabolic Disease
    Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-13C6,15N TFA
  • HY-13582A
    Carbendazim hydrochloride

    		Fungal Parasite Infection Cancer
    Carbendazim hydrochloride is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim hydrochloride is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
    Carbendazim hydrochloride
  • HY-13582
    Carbendazim
    5 Publications Verification

    		 Fungal Parasite Infection Cancer
    Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
    Carbendazim

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: